Cargando…
Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer
PURPOSE: The aim of the study is to present a new planning approach to provide better planning target volume (PTV) coverage and reduce bladder and rectum dose with hybrid Tomo‐Helical (TH)/Tomo‐Direct (TD) radiotherapy (RT) for localized prostate cancer (LPC). METHODS: Twenty‐five LPC patients were...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504587/ https://www.ncbi.nlm.nih.gov/pubmed/34498363 http://dx.doi.org/10.1002/acm2.13406 |
_version_ | 1784581348792467456 |
---|---|
author | Karaca, Sibel Koca, Timur Sarpün, İsmail Hakkı Tunçel, Nina Korcum Şahin, Aylin Fidan |
author_facet | Karaca, Sibel Koca, Timur Sarpün, İsmail Hakkı Tunçel, Nina Korcum Şahin, Aylin Fidan |
author_sort | Karaca, Sibel |
collection | PubMed |
description | PURPOSE: The aim of the study is to present a new planning approach to provide better planning target volume (PTV) coverage and reduce bladder and rectum dose with hybrid Tomo‐Helical (TH)/Tomo‐Direct (TD) radiotherapy (RT) for localized prostate cancer (LPC). METHODS: Twenty‐five LPC patients were included in this retrospective study. TH plans, TD plans, and hybrid TH/TD plans were created. Lateral beams were used for the hybrid TD plan and the prescribed dose was 70 Gy in 28 fractions (hybrid plans were combined 45 Gy/ 18 fxs for TH and 25 Gy/10 fxs for TD). Doses of PTV (D2%, D98%, D50%, homogeneity index (HI), conformity index (CI), coverage) and organs at risk (OARs) (V50%, V35%, V25%, V5%, and V95%) were analyzed. The Wilcoxon signed‐rank test was used to analyze the difference in dosimetric parameters. p‐Value < 0.05 was considered statistically significant. RESULTS: TH plans showed better CI, and target coverage (p < 0.01) than TD and hybrid plans in all patient plan evaluations. However, TD plans D2%, D98%, and D50% doses were better than TH and hybrid plans. The HI values were similar between the three plans. Significant reductions in bladder and rectum V50%, V35%, and V25% doses (p < 0.001) were observed with hybrid plans compared to TH and TD. Penile bulb V95% and bowel V5% doses were better in the hybrid plans. Left and right femoral head V5% doses were higher in the hybrid plan compared to others (p < 0.001). CONCLUSION: Concurrently hybrid TH/TD RT plan can be a good option to reduce the doses of the rectum and bladder in the RT of LPC. |
format | Online Article Text |
id | pubmed-8504587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85045872021-10-18 Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer Karaca, Sibel Koca, Timur Sarpün, İsmail Hakkı Tunçel, Nina Korcum Şahin, Aylin Fidan J Appl Clin Med Phys Radiation Oncology Physics PURPOSE: The aim of the study is to present a new planning approach to provide better planning target volume (PTV) coverage and reduce bladder and rectum dose with hybrid Tomo‐Helical (TH)/Tomo‐Direct (TD) radiotherapy (RT) for localized prostate cancer (LPC). METHODS: Twenty‐five LPC patients were included in this retrospective study. TH plans, TD plans, and hybrid TH/TD plans were created. Lateral beams were used for the hybrid TD plan and the prescribed dose was 70 Gy in 28 fractions (hybrid plans were combined 45 Gy/ 18 fxs for TH and 25 Gy/10 fxs for TD). Doses of PTV (D2%, D98%, D50%, homogeneity index (HI), conformity index (CI), coverage) and organs at risk (OARs) (V50%, V35%, V25%, V5%, and V95%) were analyzed. The Wilcoxon signed‐rank test was used to analyze the difference in dosimetric parameters. p‐Value < 0.05 was considered statistically significant. RESULTS: TH plans showed better CI, and target coverage (p < 0.01) than TD and hybrid plans in all patient plan evaluations. However, TD plans D2%, D98%, and D50% doses were better than TH and hybrid plans. The HI values were similar between the three plans. Significant reductions in bladder and rectum V50%, V35%, and V25% doses (p < 0.001) were observed with hybrid plans compared to TH and TD. Penile bulb V95% and bowel V5% doses were better in the hybrid plans. Left and right femoral head V5% doses were higher in the hybrid plan compared to others (p < 0.001). CONCLUSION: Concurrently hybrid TH/TD RT plan can be a good option to reduce the doses of the rectum and bladder in the RT of LPC. John Wiley and Sons Inc. 2021-09-08 /pmc/articles/PMC8504587/ /pubmed/34498363 http://dx.doi.org/10.1002/acm2.13406 Text en © 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of The American Association of Physicists in Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Radiation Oncology Physics Karaca, Sibel Koca, Timur Sarpün, İsmail Hakkı Tunçel, Nina Korcum Şahin, Aylin Fidan Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer |
title | Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer |
title_full | Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer |
title_fullStr | Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer |
title_full_unstemmed | Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer |
title_short | Hybrid Tomo‐Helical and Tomo‐Direct radiotherapy for localized prostate cancer |
title_sort | hybrid tomo‐helical and tomo‐direct radiotherapy for localized prostate cancer |
topic | Radiation Oncology Physics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504587/ https://www.ncbi.nlm.nih.gov/pubmed/34498363 http://dx.doi.org/10.1002/acm2.13406 |
work_keys_str_mv | AT karacasibel hybridtomohelicalandtomodirectradiotherapyforlocalizedprostatecancer AT kocatimur hybridtomohelicalandtomodirectradiotherapyforlocalizedprostatecancer AT sarpunismailhakkı hybridtomohelicalandtomodirectradiotherapyforlocalizedprostatecancer AT tuncelnina hybridtomohelicalandtomodirectradiotherapyforlocalizedprostatecancer AT korcumsahinaylinfidan hybridtomohelicalandtomodirectradiotherapyforlocalizedprostatecancer |